Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISAR-CAUTION: Clopidogrel Tapering vs Abrupt Interruption
NCT00640679Phase 4Terminated
- Sponsor
- Deutsches Herzzentrum München
- Start
- Apr 2008
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of clopidogrel in coronary artery disease (CAD) (2 arms), sponsored by Deutsches Herzzentrum München. Primary endpoint: Composite of cardiac death, myocardial infarction, stent thrombosis, stroke, major bleeding or rehospitalization due to acute coronary syndrome at 3 months. Started Apr 2008; status: terminated.
02
Drugs
clopidogrel
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00640679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00640679.